281 related articles for article (PubMed ID: 31734299)
21. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
Faggioni M; Baber U; Sartori S; Giustino G; Cohen DJ; Henry TD; Farhan S; Ariti C; Dangas G; Gibson M; Giacoppo D; Krucoff MW; Aquino M; Chandrasekhar J; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
JACC Cardiovasc Interv; 2017 Apr; 10(7):645-654. PubMed ID: 28330641
[TBL] [Abstract][Full Text] [Related]
22. Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.
Franzone A; Piccolo R; Gargiulo G; Ariotti S; Marino M; Santucci A; Baldo A; Magnani G; Moschovitis A; Windecker S; Valgimigli M
JAMA Cardiol; 2016 Oct; 1(7):795-803. PubMed ID: 27572001
[TBL] [Abstract][Full Text] [Related]
23. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E;
J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984
[TBL] [Abstract][Full Text] [Related]
24. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.
Yu J; Baber U; Mastoris I; Dangas G; Sartori S; Steg PG; Cohen DJ; Giustino G; Chandrasekhar J; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Colombo A; Pocock S; Mehran R
JACC Cardiovasc Interv; 2016 Jul; 9(14):1461-9. PubMed ID: 27478113
[TBL] [Abstract][Full Text] [Related]
25. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
[TBL] [Abstract][Full Text] [Related]
26. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
[TBL] [Abstract][Full Text] [Related]
27. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
28. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.
Savarese G; Reiner MF; Uijl A; D'Amario D; Agewall S; Atar D; Baumgartner I; Borghi C; De Carlo M; Drexel H; Kaski JC; Kjeldsen KP; Kucher N; Lund LH; Niessner A; Semb AG; Schmidt TA; Sulzgruber P; Tamargo J; Vitale C; Wassmann S; Aboyans V; Lewis BS
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):86-93. PubMed ID: 31392312
[TBL] [Abstract][Full Text] [Related]
30. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Govsyeyev N; Nehler M; Conte MS; Debus S; Chung J; Dorigo W; Gudz I; Krievins D; Mills J; Moll F; Norgren L; Piffaretti G; Powell R; Szalay D; Sillesen H; Wohlauer M; Szarek M; Bauersachs RM; Anand SS; Patel MR; Capell WH; Jaeger N; Hess CN; Muehlhofer E; Haskell LP; Berkowitz SD; Bonaca MP
J Vasc Surg; 2023 Apr; 77(4):1107-1118.e2. PubMed ID: 36470531
[TBL] [Abstract][Full Text] [Related]
32. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents.
Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Colombo A; Gilard M; Palmerini T; Stone GW
Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27803041
[TBL] [Abstract][Full Text] [Related]
33. Selective Use of Anticoagulation or Dual Antiplatelet Therapy for Patients with Extra-anatomic Bypasses.
Teveris V; Columbo J; Bartline P; Goodney P; Stone D; Suckow B
Ann Vasc Surg; 2020 Jul; 66():272-281.e1. PubMed ID: 31931126
[TBL] [Abstract][Full Text] [Related]
34. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
[TBL] [Abstract][Full Text] [Related]
35. Antithrombotic treatment in peripheral artery disease.
Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
[TBL] [Abstract][Full Text] [Related]
36. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
[TBL] [Abstract][Full Text] [Related]
38. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Bittl JA; Baber U; Bradley SM; Wijeysundera DN
J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
[TBL] [Abstract][Full Text] [Related]
39. The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization.
Banerjee S; Sarode K; Vinas A; Banerjee A; Mohammad A; Brilakis ES
Curr Opin Cardiol; 2015 Sep; 30(5):525-35. PubMed ID: 26241710
[TBL] [Abstract][Full Text] [Related]
40. Efficiency and safety of dual pathway inhibition for the prevention of femoropopliteal artery restenosis in repeated endovascular interventions.
Yu Q; Chen C; Cao J; Xu J; Lu J; Yuan L
J Vasc Surg; 2024 Mar; 79(3):623-631.e2. PubMed ID: 37951514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
